siRNA Targeting against EGFR, a Promising Candidate for a Novel Therapeutic Application to Lung Adenocarcinoma | Zendy

Sumitaka Yamanaka | Zendy; Zhaodi Gu | Zendy; Masami Sato | Zendy; Rumi Fujisaki | Zendy; Kenichi Inomata | Zendy; Akira Sakurada | Zendy; Akira Inoue | Zendy; Toshihiro Nukiwa | Zendy; Takashi Kondo | Zendy; Akira Horii | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

siRNA Targeting against <i>EGFR,</i> a Promising Candidate for a Novel Therapeutic Application to Lung Adenocarcinoma

Author(s) -

Sumitaka Yamanaka,

Zhaodi Gu,

Masami Sato,

Rumi Fujisaki,

Kenichi Inomata,

Akira Sakurada,

Akira Inoue,

Toshihiro Nukiwa,

Takashi Kondo,

Akira Horii

Publication year - 2008

Publication title -

pathobiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.941

H-Index - 53

eISSN - 1423-0291

pISSN - 1015-2008

DOI - 10.1159/000113789

Subject(s) - gefitinib , kras , adenocarcinoma , cancer research , lung cancer , gene knockdown , medicine , targeted therapy , cancer , biology , epidermal growth factor receptor , cell culture , colorectal cancer , genetics

To understand the molecular pathogenesis of lung cancer and to establish a novel therapeutic application, we examined the genetic alterations in lung cancer, and studied the effects of gefitinib and siRNA-mediated knockdown of EGFR on lung cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research